Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Klassieke hairy cell leukemie' van de HOVON CLL werkgroep.

Klik HIER voor de richtlijn 'Hairy cell leukemie variant' van de HOVON CLL werkgroep.    

Literatuur

1. Falini B and Tiacci E. Hairy-cell leukemia. New Engl J Med 2024; 391:1328-41
2. Troussard at al. Hairy cell leukemia 2024: update on diagnosis, risk-stratification and treatment - Annual updates in hematological malignancies. Am J Hematol. 2024; 99:679-696
3. Ravandi F et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118:3818-23 
4. Tiacci E et al. Vemurafenib plus rituximab in patients with refractory or relapsed hairy-cell leukemia. N Engl J Med 2011; 364 (26):2507-2516
5. Falini B and Tiacci E. How I treat refractory / relapsed hairy cell leukemia with BRAF inhibitors. Blood 2022; 139:2294-2305
6. Kreitman RJ et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013; 19(24):6873–81
7. Waterfall JJ et al. High prevalence of MAP2K1 mutations in variant and IGHV4–34-expressing hairy-cell leukemias. Nat Genet. 2014; 46(1):8–10
8. Rogers KA et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 2021; 137:3473-83
9. Tiacci E et al. Venetoclax in relapsed or refractory hairy-cell leukemia. N Engl J Med 2023; 388:952-4

Ga terug naar de HCL homepage of lees meer over HCL:

• Inleiding
• Diagnostiek
• Indeling
• Behandeling
• Respons criteria
• Follow up
• Beheer en wijzigingenhistorie

Ga terug naar de algemene homepage Behandelprotocollen.